Identification of new candidate drugs for lung cancer using chemical-chemical interactions, chemical-protein interactions and a K-means clustering algorithm

被引:29
作者
Lu, Jing [1 ]
Chen, Lei [2 ]
Yin, Jun [2 ]
Huang, Tao [3 ,4 ]
Bi, Yi [1 ]
Kong, Xiangyin [3 ,4 ]
Zheng, Mingyue [5 ]
Cai, Yu-Dong [6 ]
机构
[1] Yantai Univ, Collaborat Innovat Ctr Adv Drug Delivery Syst & B, Minist Educ, Sch Pharm,Key Lab Mol Pharmacol & Drug Evaluat, Yantai 264005, Peoples R China
[2] Shanghai Maritime Univ, Coll Informat Engn, Shanghai 201306, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med SJTUSM, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China
[4] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200025, Peoples R China
[5] Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China
[6] Shanghai Univ, Coll Life Sci, Shanghai 200444, Peoples R China
基金
中国国家自然科学基金;
关键词
chemical-protein interaction; K-means clustering algorithm; lung cancer; chemical-chemical interaction; VANDETANIB PLUS DOCETAXEL; IN-SILICO PREDICTION; PHASE-II; EGFR INHIBITOR; CARBOPLATIN; CISPLATIN; ETOPOSIDE; MODELS; GROWTH; CHEMOTHERAPY;
D O I
10.1080/07391102.2015.1060161
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lung cancer, characterized by uncontrolled cell growth in the lung tissue, is the leading cause of global cancer deaths. Until now, effective treatment of this disease is limited. Many synthetic compounds have emerged with the advancement of combinatorial chemistry. Identification of effective lung cancer candidate drug compounds among them is a great challenge. Thus, it is necessary to build effective computational methods that can assist us in selecting for potential lung cancer drug compounds. In this study, a computational method was proposed to tackle this problem. The chemical-chemical interactions and chemical-protein interactions were utilized to select candidate drug compounds that have close associations with approved lung cancer drugs and lung cancer-related genes. A permutation test and K-means clustering algorithm were employed to exclude candidate drugs with low possibilities to treat lung cancer. The final analysis suggests that the remaining drug compounds have potential anti-lung cancer activities and most of them have structural dissimilarity with approved drugs for lung cancer.
引用
收藏
页码:906 / 917
页数:12
相关论文
共 57 条
[1]   Estimating Screening-Level Organic Chemical Half-Lives in Humans [J].
Arnot, Jon A. ;
Brown, Trevor N. ;
Wania, Frank .
ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2014, 48 (01) :723-730
[2]   Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer [J].
Baka, S. ;
Califano, R. ;
Ferraldeschi, R. ;
Aschroft, L. ;
Thatcher, N. ;
Taylor, P. ;
Faivre-Finn, C. ;
Blackhall, F. ;
Lorigan, P. .
BRITISH JOURNAL OF CANCER, 2008, 99 (03) :442-447
[3]  
Brahmer, 1998, Oncologist, V3, P143
[4]   Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer [J].
Brave, Sandra R. ;
Odedra, Rajesh ;
James, Neil H. ;
Smith, Neil R. ;
Marshall, Gayle B. ;
Acheson, Kerry L. ;
Baker, Dawn ;
Howard, Zoe ;
Jackson, Lynsay ;
Ratcliffe, Kirsty ;
Wainwright, Anna ;
Lovick, Susan C. ;
Hickinson, D. Mark ;
Wilkinson, Robert W. ;
Barry, Simon T. ;
Speak, Georgina ;
Ryan, Anderson J. .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39 (01) :271-278
[5]   Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer [J].
Cascone, T ;
Morelli, MP ;
Ciardiello, F .
ANNALS OF ONCOLOGY, 2006, 17 :46-48
[6]   Finding Candidate Drugs for Hepatitis C Based on Chemical-Chemical and Chemical-Protein Interactions [J].
Chen, Lei ;
Lu, Jing ;
Huang, Tao ;
Yin, Jun ;
Wei, Lai ;
Cai, Yu-Dong .
PLOS ONE, 2014, 9 (09)
[7]   A hybrid method for prediction and repositioning of drug Anatomical Therapeutic Chemical classes [J].
Chen, Lei ;
Lu, Jing ;
Zhang, Ning ;
Huang, Tao ;
Cai, Yu-Dong .
MOLECULAR BIOSYSTEMS, 2014, 10 (04) :868-877
[8]   The role of EGFR inhibitors in nonsmall cell lung cancer [J].
Ciardiello, F ;
De Vita, F ;
Orditura, M ;
Tortora, G .
CURRENT OPINION IN ONCOLOGY, 2004, 16 (02) :130-135
[9]   EMPLOYING CONFORMATIONAL ANALYSIS IN THE MOLECULAR MODELING OF AGROCHEMICALS: INSIGHTS ON QSAR PARAMETERS OF 2,4-D [J].
de Freitas, Matheus Puggina ;
Ramalho, Teodorico de Castro .
CIENCIA E AGROTECNOLOGIA, 2013, 37 (06) :485-494
[10]   Quantitative Structure-Activity Relationship Models of Clinical Pharmacokinetics: Clearance and Volume of Distribution [J].
Gombar, Vijay K. ;
Hall, Stephen D. .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2013, 53 (04) :948-957